Provided by Tiger Fintech (Singapore) Pte. Ltd.

Travere Therapeutics, Inc.

21.15
+0.39001.88%
Post-market: 21.150.00000.00%16:20 EDT
Volume:2.33M
Turnover:48.90M
Market Cap:1.88B
PE:-5.19
High:21.71
Open:21.09
Low:20.15
Close:20.76
Loading ...

Piper Sandler Sticks to Their Hold Rating for Travere Therapeutics (TVTX)

TIPRANKS
·
Yesterday

Travere Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
Yesterday

Travere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue Estimates

Zacks
·
Yesterday

Earnings Flash (TVTX) Travere Therapeutics Q1 Adjusted Loss Per Share $0.19 vs. FactSet Est Loss $0.36

MT Newswires Live
·
Yesterday

BRIEF-Travere Therapeutics Q1 EPS USD -0.47 Vs. IBES Estimate USD -0.54

Reuters
·
Yesterday

Travere Therapeutics Q1 EPS USD -0.47 VS. Ibes Estimate USD -0.54

THOMSON REUTERS
·
Yesterday

Press Release: Travere Therapeutics Reports First Quarter 2025 Financial Results

Dow Jones
·
Yesterday

Travere, CSL Vifor Receive EU Marketing Approval for Filspari in IgA Nephropathy

MT Newswires Live
·
29 Apr

Travere Therapeutics and CSL Vifor Announce Standard EU Approval of Filspari® (Sparsentan) for Iga Nephropathy

THOMSON REUTERS
·
29 Apr

Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy

Business Wire
·
29 Apr

Travere, CSL Vifor announce EC approval of Filspari marketing authorization

TIPRANKS
·
29 Apr

BRIEF-CSL Vifor And Travere Therapeutics Announce Standard EU Approval For Filspari® In Iga Nephropathy

Reuters
·
29 Apr

CSL Vifor and Travere Therapeutics Announce Standard EU Approval for Filspari® in Iga Nephropathy

THOMSON REUTERS
·
29 Apr

Press Release: Travere Therapeutics to Report First Quarter 2025 Financial Results

Dow Jones
·
25 Apr

Exploring 3 High Growth Tech Stocks In The US Market

Simply Wall St.
·
24 Apr

Travere Therapeutics Price Target Maintained With a $47.00/Share by Guggenheim

Dow Jones
·
14 Apr

Travere Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
10 Apr

U.S. RESEARCH ROUNDUP- Carnival, JLL, Microsoft

Reuters
·
10 Apr

Travere Therapeutics Inc : Canaccord Genuity Raises Target Price to $47 From $45

THOMSON REUTERS
·
10 Apr

Novavax (NVAX) Soars 11.4%: Is Further Upside Left in the Stock?

Zacks
·
07 Apr